- •An increase in FIB-4 value over time was associated with risk for developing cirrhosis and HCC in NAFLD patients.
- •Patients with NAFLD that had persistently high FIB-4 values (>2.67) at baseline and at 3 years had over a 50-fold increased risk for developing HCC than NAFLD patients with persistently low FIB-4 (<1.45) values.
- •75% of patients had low risk, 21% had indeterminate risk (1.45-2.67) and 4% had high risk for advanced fibrosis based on FIB-4 value at baseline. More than 50% of NAFLD patients remained within the same FIB-4 risk group after 3 years.
- •Repeating FIB-4 measurements in clinical practice was strongly associated with progression to cirrhosis and HCC in NAFLD patients.
Background & Aims
Impact and implications
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
- Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes.Hepatology. 2016; 64: 73-84
- Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention.Nat Rev Gastroenterol Hepatol. 2018; 15: 11-20
- Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study.Gastroenterology. 2011; 140: 124-131
- Prevalence of Nonalcoholic Steatohepatitis-Associated Cirrhosis in the United States: An Analysis of National Health and Nutrition Examination Survey Data.Am J Gastroenterol. 2017; 112: 581-587
- Trends in the Burden of Nonalcoholic Fatty Liver Disease in a United States Cohort of Veterans.Clin Gastroenterol Hepatol. 2016; 14 (301-308 e301-302)
- Outcomes of curative treatment for hepatocellular cancer in nonalcoholic steatohepatitis versus hepatitis C and alcoholic liver disease.Hepatology. 2012; 55: 1809-1819
- NAFLD may be a common underlying liver disease in patients with hepatocellular carcinoma in the United States.Hepatology. 2002; 36: 1349-1354
- Risk of Hepatocellular Cancer in Patients With Non-Alcoholic Fatty Liver Disease.Gastroenterology. 2018; 155 (e1822): 1828-1837
- Global epidemiology of NAFLD-related HCC: trends, predictions, risk factors and prevention.Nature Reviews Gastroenterology & Hepatology. 2020;
- Nonalcoholic Fatty Liver Disease: Epidemiology, Natural History, and Diagnostic Challenges.Hepatology. 2016; 64: 954
- Global epidemiology of NAFLD-related HCC: trends, predictions, risk factors and prevention.Nat Rev Gastroenterol Hepatol. 2021; 18: 223-238
- Conceptual Model for the Hepatocellular Carcinoma Screening Continuum: Current Status and Research Agenda.Clin Gastroenterol Hepatol. 2020;
- Association Between Fibrosis Stage and Outcomes of Patients With Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis.Gastroenterology. 2020; 158: 1611-1625 e1612
- Long-Term Risk of Hepatocellular Carcinoma in HCV Patients Treated With Direct Acting Antiviral Agents.Hepatology. 2020; 71: 44-55
- Risk of Cirrhosis and Hepatocellular Cancer in Patients With NAFLD and Normal Liver Enzymes.Hepatology. 2020; 72: 1242-1252
- Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection.Hepatology. 2006; 43: 1317-1325
- Accurate Identification of Fatty Liver Disease in Data Warehouse Utilizing Natural Language Processing.Digestive Diseases and Sciences. 2017; 62: 2713-2718
- Comparison of noninvasive markers of fibrosis in patients with nonalcoholic fatty liver disease.Clin Gastroenterol Hepatol. 2009; 7: 1104-1112
- A comprehensive definition for metabolic syndrome.Dis Model Mech. 2009; 2: 231-237
- Immortal Time Bias in Observational Studies of Time-to-Event Outcomes: Assessing Effects of Postmastectomy Radiation Therapy Using the National Cancer Database.Cancer Control. 2018; 251073274818789355
- Age as a Confounding Factor for the Accurate Non-Invasive Diagnosis of Advanced NAFLD Fibrosis.Official journal of the American College of Gastroenterology | ACG. 2017; 112: 740-751
- Ability of Noninvasive Scoring Systems to Identify Individuals in the Population at Risk for Severe Liver Disease.Gastroenterology. 2020; 158: 200-214
- Repeated FIB-4 measurements can help identify individuals at risk of severe liver disease.J Hepatol. 2020; 73: 1023-1029
- Surveillance for Hepatocellular Carcinoma: Current Best Practice and Future Direction.Gastroenterology. 2019; 157: 54-64
- AGA Clinical Practice Update on Screening and Surveillance for Hepatocellular Carcinoma in Patients With Nonalcoholic Fatty Liver Disease: Expert Review.Gastroenterology. 2020; 158: 1822-1830
- Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases.Hepatology. 2018; 68: 723-750
- Electronic address eee, Clinical Practice Guideline P, Chair, representative EGB, Panel m. EASL Clinical Practice Guidelines on non-invasive tests for evaluation of liver disease severity and prognosis - 2021 update.J Hepatol. 2021; 75: 659-689